Circulating tumor markers in breast cancer: accepted utilities and novel prospects (Q33538453)

27 July 2017

1 reference

title

Circulating tumor markers in breast cancer: accepted utilities and novel prospects (English)

1 reference

27 July 2017

1 reference

Stearns V

1

1 reference

27 July 2017

Yamauchi H

series ordinal

2

1 reference

27 July 2017

Hayes DF

series ordinal

3

1 reference

27 July 2017

language of work or name

English

0 references

publication date

1 January 1998

1 reference

Breast Cancer Research and Treatment

27 July 2017

published in

1 reference

27 July 2017

volume

52

1 reference

27 July 2017

issue

1-3

1 reference

27 July 2017

page(s)

239-259

1 reference

Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers

27 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful?

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

Cellular expression of lymphocyte function associated antigens and the intercellular adhesion molecule-1 in normal tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

Complete genomic sequence and analysis of 117 kb of human DNA containing the gene BRCA1

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

Prognostic significance of circulating P53 antibodies in patients undergoing surgery for locoregional breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

Absence of p53 autoantibodies in a significant proportion of breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

The relationship between serum p53 autoantibodies and characteristics of human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

CEA in tumors of other than colorectal origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

Immunohistochemical markers in the identification of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

Prostate-specific antigen in serum of women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

Prognostic factors and treatment decisions in axillary-node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

Low levels of basic fibroblast growth factor (bFGF) are associated with a poor prognosis in human breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

Serum concentration of hepatocyte growth factor in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

Breast cancer prognostic factors: evaluation guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

Circulating concentrations of insulin-like growth factor I and risk of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. Adopted on November 7, 1997 by the American Society of Clinical Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

7 January 2021

Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

7 January 2021

Circulating and tissue markers in the longitudinal management of breast cancer patients.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

7 January 2021

Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

7 January 2021

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

7 January 2021

Screening for breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

7 January 2021

Efficacy of screening mammography among women aged 40 to 49 years and 50 to 69 years: comparison of relative and absolute benefit

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

7 January 2021

Comparison of mammary serum antigen assay with mammography in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

7 January 2021

Comparative study of mammography and mammary serum antigen estimation for breast cancer screening

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

7 January 2021

CA15-3, CASA, MSA, and TPS as diagnostic serum markers in breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

7 January 2021

High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

7 January 2021

Evaluation of a breast cyst fluid protein detectable in the plasma of breast carcinoma patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

7 January 2021

ElevatederbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

7 January 2021

Detection of C-ERBB-2 Related Protein in Sera from Breast Cancer Patients Relationship to ERBB2 gene amplification and c-erbB-2 protein overexpression in tumour

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

7 January 2021

Increased cathepsin D level in the serum of patients with metastatic breast carcinoma detected with a specific pro-cathepsin D immunoassay

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

7 January 2021

Preoperative staging of primary breast cancer. A multicentric study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

7 January 2021

Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

7 January 2021

p53 status and the efficacy of cancer therapy in vivo

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

7 January 2021

Should we treat HER, too?

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

7 January 2021

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

7 January 2021

Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

7 January 2021

The prognostic significance of c-erbB-2 serum protein in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

7 January 2021

Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

7 January 2021

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

7 January 2021

Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

7 January 2021

Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

7 January 2021

Treatment of disease-negative but mucin-like carcinoma-associated antigen-positive breast cancer patients with tamoxifen: preliminary results of a prospective controlled randomized trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

7 January 2021

Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

7 January 2021

Circulating CA 549 and other associated antigens in breast cancer patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

7 January 2021

Prognostic significance of serum c-erbB-2 protein in breast cancer patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006137619153

7 January 2021

Identifiers

DOI

10.1023/A:1006137619153

1 reference

Dimensions Publication ID

27 July 2017

1002064022

0 references

1 reference